Launch week offerEnds in00h00m00s

annual Promonthly Pro

Antonin Schmitt

Professor

Centre Georges-François Leclerc

France

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in France

About

Professor Antonin Schmitt is a faculty member at the Centre Georges François Leclerc in France. His research focuses on pharmacokinetics, the management of cancer therapies, and the toxicities associated with various treatments. Recent articles authored by Professor Schmitt delve into topics such as the impact of surgical procedures on drug exposure, prevention of drug-related toxicities, and innovative approaches to improve patient care in oncology.

Articles (16)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (3)

Thierry Buclin

SWITZERLAND

View details

Monia Guidi

Senior researcher

Lausanne University Hospital

SWITZERLAND

View details

Jean-Francois Merlin

L'Institut Agro Dijon

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Antonin Schmitt

Research Interests

Make your next move.

Explore related searches

About

Articles (16)

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics

PK and PK/PD Modeling of Bcl2 Inhibitor S65487 in Patients With AML and Investigation of Nonlinearity With Microdosing

Impact of gastrectomy on cabozantinib exposure: Clinical case of a patient with clear renal cell carcinoma

Prevention and management of PARP inhibitor-related haematological toxicities in prostate cancer: French expert opinion using the Delphi method

The harms of inappropriate digoxin prescribing in cancer patients : a drug-drug interaction with posaconazole

Improving olaparib exposure to optimize adverse effects management

Pharmacokinetics and Pharmacodynamic of Alpelisib.

Novel Fat Taste Receptor Agonists Curtail Progressive Weight Gain in Obese Male Mice.

Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.

[Practical management of PARP inhibitors: A French DELPHI consensus].

Smartphone-based application and nurses' interventions for symptoms monitoring in patients treated with oral anticancer agents: A 1-year follow-up in a tertiary cancer center.

Adherence to oral anti-cancer therapies in older patients is similar to that of younger patients.

Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.

Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach

Endoxifen exposure after 5 weeks of preoperative tamoxifen is predictive of long-term outcome of operable hormone receptor positive (HR+) HER2-early breast cancer

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients

Collaborators (3)

Thierry Buclin

Monia Guidi

Jean-Francois Merlin

Make your next move.